Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01386476
Other study ID # 110195
Secondary ID 11-M-0195
Status Completed
Phase
First received
Last updated
Start date June 15, 2011
Est. completion date September 1, 2016

Study information

Verified date September 1, 2016
Source National Institutes of Health Clinical Center (CC)
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Background:

- The blood-brain barrier helps protect the brain from infections and toxins in the blood stream. But it can also prevent certain drugs from reaching the brain to treat diseases or other problems. Researchers are interested in chemicals that will help show how the barrier works. One possible chemical, (18F)FCWAY, may be useful for studying the barrier. More tests are needed to determine how effective it is.

Objectives:

- To test whether (18F)FCWAY can be used to help study the blood-brain barrier.

Eligibility:

- Healthy volunteers between 18 and 50 years of age.

Design:

- This study requires a screening visit and two scanning visits.

- Participants will be screened with a physical exam and medical history. They will also have blood and urine tests.

- At the first scanning visit, participants will have a magnetic resonance imaging scan to provide baseline images of the brain.

- Before the second visit, some participants will stay overnight in the hospital. They will receive the drug tariquidar, which may help the (18F)FCWAY show the blood-brain barrier more clearly.

- At the second scanning visit, all participants will have a positron emission tomography scan with (18F)FCWAY to see how well the drug shows the blood-brain barrier on the scan.


Description:

Objective:

We use the radioligand [(11)C]dLop (N-desmethyl-loperamide) in positron emission tomography (PET) studies to measure function of P-gp, an efflux transporter at the blood-brain barrier. Because [(11)C]dLop is an avid substrate for P-gp, we see almost no radioactivity in brain at baseline in healthy volunteers. However, we do see increased radioactivity in brain in some patients with dementia, or when we co-administer a medication which blocks the function of P-gp. While [(11)C]dLop is useful for detecting increased radioactivity in brain, a disadvantage of [(11)C]dLop is that it is not useful for detecting decreased radioactivity in brain. The reason for this is that we have a floor effect, where we are unable to detect less radioactivity than zero. Preclinical studies indicate that increases in P-gp activity (which would manifest as decreased radioactivity in brain) correlate with drug-resistant epilepsy and HIV. To better understand diseases associated with not only increased but also decreased P-gp activity, we wish to identify a radioligand which is a moderate substrate of P-gp. We suspect that [(18)F]FCWAY is a moderate substrate for P-gp, because some radioligand gets into brain at baseline, but more gets into brain after administering a drug (disulfiram) which inhibits P-gp. The objective of this study is to determine whether the serotonin 1A antagonist [(18)F]FCWAY is a substrate of P-gp by determining whether the P-gp inhibitor, tariquidar, increases uptake of the radioligand into brain.

Study Population:

We will study up to 45 healthy adults, ages 18-50. Participants must be free of medications, with the exception of birth control pills, as medications may confound our data. or iii patients who received a single PET scan as stated under i), will be invited back to have the option of receiving the second PET scan with tariquidar. A maximum of 15 ubjects will receive both scans.

Design:

Healthy adults will undergo either 1) a single PET scan of the brain with [(18)F]FCWAY (at baseline, or during infusion of intravenous tariquidar or 2) two PET scans (both a baseline and a tariquidar scan).

Outcome Measures:

If [(18)F]FCWAY is a substrate of P-gp, pre-treatment with tariquidar will increase its brain uptake of [(18)F]FCWAY and delay the time of peak uptake.


Recruitment information / eligibility

Status Completed
Enrollment 18
Est. completion date September 1, 2016
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 50 Years
Eligibility - INCLUSION CRITERIA:

Subjects must be 18 to 50 years old.

Subjects must be currently healthy, based on history, physical exam, and laboratory testing.

With the exception of birth control pills, subjects must agree not to take any medication, prescription or over-the-counter, one week before and one week after receiving tariquidar.

Subjects must be able and willing to give written informed consent.

EXCLUSION CRITERIA:

Subjects routinely taking prescription medications, except birth control pills. That is, subjects should not discontinue mediations merely to participate in this study.

Subjects taking recreational or over-the-counter drugs.

Subjects will be excluded if they have any current Axis I diagnosis, including a current diagnosis of alcohol or substance abuse.

History of psychotic symptoms or suicide attempt.

Head trauma resulting in a period of unconsciousness lasting longer than 10 minutes or a history of seizures, because seizures may increase the function of P-gp.

Recent exposure to radiation (i.e., PET from other research) which when combined with this study would be above the allowable limits.

Pregnancy or breast feeding.

Positive urine drug screen.

Unlikely to tolerate small, enclosed spaces, as in the MRI.

Metallic foreign bodies that would be affected by the MRI magnet or fear of enclosed spaces likely to make the subject unable to complete an MRI scan.

Positive HIV status.

Inability to lie flat on camera bed for about 2 (Omega) hours.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda Maryland

Sponsors (1)

Lead Sponsor Collaborator
National Institute of Mental Health (NIMH)

Country where clinical trial is conducted

United States, 

References & Publications (3)

Kannan P, John C, Zoghbi SS, Halldin C, Gottesman MM, Innis RB, Hall MD. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther. 2009 Oct;86(4):368-77. doi: 10.1038/clpt.2009.138. Epub 2009 Jul 22. Review. — View Citation

Liow JS, Lu S, McCarron JA, Hong J, Musachio JL, Pike VW, Innis RB, Zoghbi SS. Effect of a P-glycoprotein inhibitor, Cyclosporin A, on the disposition in rodent brain and blood of the 5-HT1A receptor radioligand, [11C](R)-(-)-RWAY. Synapse. 2007 Feb;61(2):96-105. — View Citation

Zhang XY, Yasuno F, Zoghbi SS, Liow JS, Hong J, McCarron JA, Pike VW, Innis RB. Quantification of serotonin 5-HT1A receptors in humans with [11C](R)-(-)-RWAY: radiometabolite(s) likely confound brain measurements. Synapse. 2007 Jul;61(7):469-77. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Tariquidar will increase uptake of 18F-FCWAY in brain
Secondary Tariquidar will delay brain peak of 18F-FCWAY
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04516395 - Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae N/A
Terminated NCT00319150 - REPEAT Study - Resistance to ErythroPoietin Effectiveness Algorithm Trial Phase 3
Completed NCT00563875 - Laboratory Aspirin Resistance in Diabetics and Non-Diabetics N/A
Completed NCT00389129 - Danish Aspirin Resistance Trial - Pilot Study N/A
Terminated NCT00193947 - An Evaluation of the Development of Nevirapine Induced Mutations in HIV Patients Initiating or Discontinuing Combination Antiretroviral Therapy Phase 4
Enrolling by invitation NCT06037564 - B-free Multistage Trial Phase 4
Completed NCT04326868 - Human Soil Transmitted Helminths (STH) Resistance to Benzimidazole in School Aged Children Living in Gabon Phase 4
Completed NCT01039480 - Aspirin and Clopidogrel Resistance Study N/A
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Active, not recruiting NCT00457236 - Effect of Clopidogrel Loading and Risk of PCI N/A
Completed NCT02792816 - Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar N/A
Recruiting NCT04990596 - Mechanisms fo Clopidogrel Resistance in Older Adults (CEPAGE)
Recruiting NCT03401957 - The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment N/A
Completed NCT04404582 - Clinical Characteristics for the Critical Ill Patients With Klebsiella Pneumoniae Infection
Completed NCT02401204 - Bacterial Transmission Dynamics Study
Completed NCT03114098 - Pharmacogenetics Anomaly Research in Children and Adolescents With Pharmacological Resistance to Psychotropic Drugs N/A
Recruiting NCT03361267 - Comparison of Bismuth Containing Quadruple Therapy and Based Tailored Therapy for H. Pylori Infection N/A
Completed NCT00302913 - Efficacy of Adjusted Clopidogrel Dose in Patients With Insufficient Platelet Inhibition N/A
Completed NCT04833231 - The Relationship Between Renal Functions and Multi Drug Resistant Organisms
Completed NCT00965042 - Effect of Ceftobiprole on Human Intestinal Microflora Phase 1